Results 171 to 180 of about 150,813 (294)

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

open access: yesCancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu   +7 more
wiley   +1 more source

L1CAM Promotes the Infiltrative Properties of Patient‐Derived Glioblastoma Cells

open access: yesCancer Science, EarlyView.
In vivo validation of L1CAM‐mediated GBM infiltration. Orthotopic transplantation of L1CAM‐expressing GBM cells into mouse brains demonstrated that L1CAM significantly promotes tumor cell infiltration and expansion in the brain parenchyma, confirming its critical role in the aggressive progression of GBM.
Asako Katsuma   +10 more
wiley   +1 more source

Hypoxia Exacerbates Periapical Periodontitis‐Associated Pathological Bone Loss via the Hypoxia‐Inducible Factor‐2α‐Calmodulin‐Dependent Protein Kinase IV Axis

open access: yesCell Proliferation, EarlyView.
Hypoxia exposure activates HIF‐2α, which binds to the Camk4 promoter to enhance RANKL‐mediated osteoclast differentiation, leading to aggravated alveolar bone resorption in periapical periodontitis. ABSTRACT Periapical periodontitis is one of the most common inflammatory bone destructive diseases. Epidemiological evidence suggests that hypoxia exposure,
Kang Gao   +11 more
wiley   +1 more source

Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30‐positive cutaneous T‐cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce.
Patrick Schummer   +10 more
wiley   +1 more source

Tumor Lysis Syndrome After mFOLFOX6 Administration for Ascending Colon Cancer. [PDF]

open access: yesCureus
Kano Y   +8 more
europepmc   +1 more source

Real‐World Selection of Venetoclax‐Obinutuzumab Versus BTK Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Introduction Novel targeted agents have transformed the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including continuous BTK inhibitor (BTKi) therapy and time‐limited regimens such as venetoclax‐obinutuzumab (Ven‐O) and ibrutinib‐venetoclax (I + V).
Rebecca Tidswell   +7 more
wiley   +1 more source

Continuous hemodiafiltration during chemotherapy for acute kidney injury in spontaneous tumor lysis syndrome due to high-grade B-cell lymphoma: a case report. [PDF]

open access: yesCEN Case Rep
Kawamura N   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy